Mounjaro (tirzepatide) is a dual GIP/GLP-1 receptor agonist licensed in the UK for type 2 diabetes and weight management. Whilst gastrointestinal side effects such as nausea and diarrhoea are well documented, some patients report experiencing body aches during treatment. Although myalgia is listed as an uncommon adverse reaction in the Summary of Product Characteristics, the relationship between Mounjaro and musculoskeletal discomfort remains an area of ongoing observation. This article examines the evidence, explores potential mechanisms, and provides guidance on managing body aches whilst taking Mounjaro.
Quick Answer: Mounjaro (tirzepatide) lists myalgia as an uncommon side effect, affecting fewer than 1 in 100 patients, though some individuals report body aches during treatment.
Mounjaro (tirzepatide) is a prescription medicine licensed in the UK for the treatment of type 2 diabetes mellitus and, more recently, for weight management in adults with obesity or overweight with weight-related comorbidities. In England, NHS access to Mounjaro for weight management is restricted to patients meeting specific NICE eligibility criteria. It belongs to a novel class of medications known as dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists. By activating both GIP and GLP-1 receptors, Mounjaro enhances insulin secretion when blood glucose levels are elevated, suppresses glucagon release, slows gastric emptying, and reduces appetite—mechanisms that collectively improve glycaemic control and promote weight loss.
As with all medications, Mounjaro is associated with a range of side effects, some of which are common and generally mild to moderate in severity. According to the UK Summary of Product Characteristics (SmPC), the most frequently reported adverse effects are gastrointestinal in nature, including nausea, vomiting, diarrhoea, constipation, abdominal pain, decreased appetite, and gastro-oesophageal reflux disease. These symptoms typically emerge during the initial weeks of treatment or following dose escalation (Mounjaro is usually started at a low dose of 2.5mg once weekly and gradually increased) and often diminish over time as the body adjusts to the medication.
Other recognised side effects include injection site reactions (such as redness, swelling, or itching), fatigue, headache, dizziness, and alopecia (hair loss). Hypoglycaemia (low blood sugar) may occur, particularly when Mounjaro is used in combination with other glucose-lowering agents such as insulin or sulphonylureas. Serious but rare adverse effects include pancreatitis, gallbladder disease, and allergic reactions. Understanding the full spectrum of potential side effects is essential for patients and healthcare professionals to ensure safe and effective use of Mounjaro, and to distinguish expected reactions from those requiring medical attention.
Mounjaro® is the most innovative GLP-1 medication proven to dramatically curb appetite, hunger, and cravings to help professional men achieve substantial weight loss.
Start Here
Wegovy® is a weekly injectable GLP-1 medication with proven effectiveness in reducing appetite, hunger, and cravings to help busy professionals lose significant weight.
Start HereBody aches—also referred to as myalgia or musculoskeletal pain—are not prominently listed among the most common side effects of Mounjaro in the official Summary of Product Characteristics (SmPC) approved by the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA). According to the SmPC, myalgia is listed as an uncommon adverse reaction (affecting less than 1 in 100 but more than 1 in 1,000 patients). The pivotal clinical trials that led to Mounjaro's approval, including the SURPASS programme for type 2 diabetes and the SURMOUNT trials for weight management, did not identify body aches as a frequent or statistically significant adverse event compared to placebo.
However, post-marketing surveillance and patient-reported experiences suggest that some individuals taking Mounjaro do report generalised body aches, muscle pain, or joint discomfort. These reports are anecdotal and have not been systematically quantified in large-scale studies, meaning there is limited evidence for a causal link between Mounjaro and body aches at present. It is important to recognise that the relatively low frequency of documented musculoskeletal symptoms in clinical trials does not definitively rule out the possibility that a minority of patients may experience such effects.
The relationship between GLP-1 receptor agonists (and by extension, dual GIP/GLP-1 agonists like Mounjaro) and body aches remains an area of ongoing observation. Some patients using similar medications have reported muscle or joint pain, though the mechanisms and incidence are not well characterised. Healthcare professionals should remain vigilant to patient reports of body aches and consider them in the broader context of the individual's medical history, concurrent medications, and other potential causes of musculoskeletal discomfort.
Patients who suspect they are experiencing side effects from Mounjaro should report them to their GP and can also report directly to the MHRA through the Yellow Card scheme, which helps monitor the safety of medicines after they are licensed.
While there is limited definitive evidence linking Mounjaro directly to body aches, several hypothetical mechanisms may explain why some patients experience musculoskeletal discomfort during treatment. These explanations remain largely speculative and require further research to establish their validity.
One potential factor is rapid weight loss. Mounjaro is highly effective at promoting significant weight reduction, and substantial or rapid weight loss can place mechanical stress on muscles, joints, and connective tissues as the body adapts to changes in body composition and load distribution. This can manifest as generalised aches, particularly in weight-bearing joints such as the knees, hips, and lower back.
Another consideration is dehydration and electrolyte imbalance. Gastrointestinal side effects such as nausea, vomiting, and diarrhoea—common with Mounjaro—can lead to fluid and electrolyte losses. Dehydration and imbalances in sodium, potassium, or magnesium may contribute to muscle cramps, weakness, and generalised body aches. Ensuring adequate hydration is important for patients experiencing gastrointestinal symptoms, in line with NHS guidance on managing dehydration. If electrolyte imbalances are suspected, blood tests should be performed before considering supplementation.
Fatigue and reduced caloric intake associated with Mounjaro's appetite-suppressing effects may also play a role. Patients consuming significantly fewer calories may experience low energy levels, which can be perceived as muscle weakness or achiness. Additionally, some individuals may inadvertently reduce their intake of essential nutrients, including protein, which is vital for muscle health and recovery.
Finally, it is worth noting that immune-mediated or inflammatory responses to the medication, though rare, could theoretically contribute to musculoskeletal symptoms in susceptible individuals. However, this remains highly speculative and would require further investigation. Understanding these potential mechanisms can help patients and clinicians identify modifiable factors and implement strategies to alleviate discomfort.
When a patient taking Mounjaro reports body aches, it is essential to conduct a thorough clinical assessment to determine whether the symptoms are related to the medication or attributable to other causes. Body aches are a non-specific symptom with a wide differential diagnosis, and a systematic approach is necessary to avoid misattribution.
Temporal relationship is a key consideration. If body aches began shortly after starting Mounjaro or following a dose increase, this may suggest a possible association. Conversely, if the symptoms predate the initiation of Mounjaro or have been longstanding, alternative explanations should be explored. Common musculoskeletal conditions such as osteoarthritis, fibromyalgia, polymyalgia rheumatica, or inflammatory arthritis can cause widespread body aches and should be considered, particularly in older adults or those with relevant risk factors. Polymyalgia rheumatica typically presents in adults over 50 with pronounced morning stiffness and elevated inflammatory markers (ESR/CRP).
Infectious causes must also be excluded. Viral illnesses such as influenza, COVID-19, or other respiratory infections commonly present with myalgia and generalised body aches. A careful history of recent illness, fever, or other systemic symptoms can help identify an infectious aetiology. Additionally, certain medications—including statins, which are frequently prescribed alongside diabetes treatments—are well-known causes of muscle pain and should be reviewed.
Metabolic and endocrine disorders such as hypothyroidism, vitamin D deficiency, or electrolyte disturbances can also manifest as muscle aches and fatigue. Blood tests, including thyroid function (TSH), vitamin D levels, electrolytes (U&Es), creatine kinase (CK), and inflammatory markers (ESR/CRP), may be warranted depending on the clinical context. Finally, lifestyle factors such as increased physical activity, poor sleep, or stress can contribute to musculoskeletal discomfort and should be explored during the consultation. A comprehensive evaluation ensures that body aches are appropriately investigated and managed.
For patients experiencing body aches while taking Mounjaro, several practical strategies can help alleviate discomfort and improve quality of life. First and foremost, maintaining adequate hydration is essential, particularly for those experiencing gastrointestinal side effects. Drinking plenty of water throughout the day and considering oral rehydration solutions if diarrhoea or vomiting is present can help prevent dehydration-related muscle aches, in line with NHS guidance on managing dehydration.
Ensuring balanced nutrition is equally important. Patients should aim to consume a well-rounded diet that includes sufficient protein, vitamins, and minerals to support muscle health. If appetite suppression makes it difficult to meet nutritional needs, smaller, more frequent meals or consultation with a dietitian may be beneficial. Supplementation with vitamin D, magnesium, or other nutrients should only be considered if deficiencies are identified through blood tests.
Gentle physical activity can help reduce musculoskeletal discomfort. Low-impact exercises such as walking, swimming, or yoga can improve circulation, reduce stiffness, and promote overall well-being. However, patients should avoid overexertion, particularly during periods of rapid weight loss or fatigue. Adequate rest and sleep are also crucial for muscle recovery and overall health.
Over-the-counter pain relief may be appropriate for managing mild to moderate body aches. Paracetamol is generally safe and effective for musculoskeletal pain. Non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen may also be used, but patients should consult their GP or pharmacist first, particularly if they have underlying kidney disease, cardiovascular conditions, or gastrointestinal issues. NSAIDs should be avoided during periods of dehydration due to increased risk of kidney injury. Topical analgesics or heat therapy (such as warm baths or heating pads) can provide additional relief.
People with diabetes should follow 'sick day rules' if experiencing significant gastrointestinal symptoms, ensuring they maintain fluid intake and monitor blood glucose levels more frequently. Those taking insulin or sulphonylureas may need dose adjustments to prevent hypoglycaemia during periods of reduced food intake.
If body aches persist despite these measures, or if they are severe or worsening, patients should seek medical advice. Any suspected adverse reactions to Mounjaro should be reported through the MHRA Yellow Card scheme.
While mild, transient body aches may not require immediate medical attention, there are certain red flag symptoms that warrant prompt evaluation by a healthcare professional. Patients should contact their GP or seek urgent medical advice if they experience severe or worsening pain that does not respond to simple analgesia, as this may indicate an underlying condition requiring investigation.
Muscle weakness, particularly if progressive or affecting daily activities such as climbing stairs or lifting objects, should be assessed promptly. Weakness accompanied by dark-coloured urine may suggest rhabdomyolysis—a rare but serious condition involving muscle breakdown—and requires immediate medical attention. Similarly, joint swelling, redness, or warmth may indicate inflammatory arthritis or infection and should be evaluated without delay.
Patients should also seek advice if body aches are accompanied by systemic symptoms such as fever, unexplained weight loss (beyond that expected from Mounjaro), night sweats, or persistent fatigue, as these may suggest an infectious, inflammatory, or malignant process. Chest pain, shortness of breath, or palpitations occurring alongside body aches should prompt urgent assessment to exclude cardiovascular or respiratory causes.
Specific to Mounjaro, patients should stop the medication and seek immediate medical attention if they experience severe, persistent abdominal pain (which may radiate to the back) with or without vomiting, as this could indicate pancreatitis—a rare but serious side effect. Similarly, right upper abdominal pain, jaundice (yellowing of skin/eyes), or dark urine could suggest gallbladder disease, another recognised complication. Any signs of a severe allergic reaction such as rash, facial/throat swelling, or difficulty breathing require emergency care.
For people with diabetes taking Mounjaro alongside insulin or sulphonylureas, recurrent or severe hypoglycaemia (low blood sugar) should prompt urgent medical review and medication adjustment.
If symptoms are severe or concerning, patients should contact NHS 111 for urgent advice or call 999/go to A&E in an emergency. For less urgent concerns, they should consult their GP. In all cases, open communication between patients and healthcare professionals is essential to ensure safe, effective, and individualised care.
Body aches (myalgia) are listed as an uncommon side effect of Mounjaro, affecting fewer than 1 in 100 patients. The most common side effects are gastrointestinal, including nausea, vomiting, and diarrhoea.
Maintain adequate hydration, ensure balanced nutrition, and consider over-the-counter pain relief such as paracetamol. If body aches are severe, persistent, or accompanied by red flag symptoms such as muscle weakness or fever, contact your GP promptly.
Seek urgent medical advice if you experience severe or worsening pain, progressive muscle weakness, dark urine, joint swelling, fever, severe abdominal pain, or signs of an allergic reaction. Contact NHS 111 for urgent concerns or call 999 in an emergency.
All medical content on this blog is created based on reputable, evidence-based sources and reviewed regularly for accuracy and relevance. While we strive to keep content up to date with the latest research and clinical guidelines, it is intended for general informational purposes only.
DisclaimerThis content is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional with any medical questions or concerns. Use of the information is at your own risk, and we are not responsible for any consequences resulting from its use.
